Business
iSpecimen Announces Organizational Changes to Enhance Operational Efficiencies and Drive Profitability
Company to Focus on Core Revenue Drivers, New Revenue Growth Opportunities from Recently Launched Sequencing Procurement Program and Expense Reductions
About this update from Ispecimen Inc.
[{"type":"text","content":"Company to Focus on Core Revenue Drivers, New Revenue Growth Opportunities from Recently Launched Sequencing Procurement Program and Expense Reductions\nLEXINGTON, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today that the Board of Directors has approved an organizational restructuring plan to improve operational performance and drive shareholder value. iSpecimen announced immediate headcount reductions of approximately 20% of the Company’s total workforce and additional expense reductions after streamlining operations and rationalizing resources to focus on key market opportunities. Recently, the Company completed its implementation of lines of business teams and next day quotes to shorten sales cycles, improve quote-to-purchase order ratios, increase fulfillment and accelerate revenue generation. As a result of these changes, monthly expenses related to headcount, including other employee turnover during the year, as well as all other monthly operational costs, are expected to decrease by approximately 29% and 52%, respectively, compared to the average monthly costs for the first eight months of the year. “The Company believes that the investments made during the first half of the year should allow the iSpecimen Marketplace to remain a leading source for researchers in need of biospecimens. We remain committed to becoming cash flow neutral and then cash flow positive as quickly as possible,” said Tracy Curley, iSpecimen’s CEO. iSpecimen recently announced the launch of its virtual cancer sequencing procurement program aimed at providing researchers with consistent and direct access to cancer tumor tissues. The genetic signatures of cancer tumor tissues provide important information necessary to develop new treatments and diagnostics. Through this new offering, cancer researchers can advance their work by efficiently accessing these highly sought tumor tissues from iSpecimen, overcoming the existing manual, time-consuming and costly process of requesting biospecimen samples from multiple sources and suppliers. Ms. Curley concluded, “Capitalizing on our market position and leveraging our broad supplier network, we s...